ViroPharma is hoping to expand its orphan drug portfolio by forging a deal to acquire Sweden’s DuoCort Pharma for up to SEK1080 M (US$165 M). The closing of the acquisition is dependent upon three conditions being satisfied, including the approval of DuoCort’s Plenadren® (hydrocortisone, modified-release tablet) by the EC. If approved, Plenadren will be the first new drug for the treatment of adrenal insufficiency in over 50 years.